• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2013 - Product Image

Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2013

  • Published: September 2013
  • 52 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Ascenion GmbH
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Oragenics, Inc.
  • MORE

Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Mycobacterium Tuberculosis Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mycobacterium Tuberculosis Infections. Mycobacterium Tuberculosis Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Mycobacterium Tuberculosis Infections.
- READ MORE >

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Mycobacterium Tuberculosis Infections Overview
Therapeutics Development
An Overview of Pipeline Products for Mycobacterium Tuberculosis Infections
Mycobacterium Tuberculosis Infections Therapeutics under Development by Companies
Mycobacterium Tuberculosis Infections Therapeutics under Investigation by Universities/Institutes
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Mycobacterium Tuberculosis Infections Therapeutics - Products under Development by Companies
Mycobacterium Tuberculosis Infections Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Mycobacterium Tuberculosis Infections Therapeutics Development
AstraZeneca PLC
GlaxoSmithKline plc
Affinium Pharmaceuticals, Inc.
Oragenics, Inc.
Ascenion GmbH
Mycobacterium Tuberculosis Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
MU-1140 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fabl Inhibitor Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MU-1140-S - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aminopyrazinamides - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tetramic Acid Analogs - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(BV-6481 + ethionamide) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDR And XDR Tuberculosis Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thuggacines - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biotin Triazoles - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mycobacterial Gyrase Inhibitor Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Riminophenazines - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KKL-35 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R-12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R-13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rAMtb-SIVgag Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mycobacterium Tuberculosis Infections Therapeutics - Drug Profile Updates
Mycobacterium Tuberculosis Infections Therapeutics - Dormant Products
Mycobacterium Tuberculosis Infections - Product Development Milestones
Featured News & Press Releases
Aug 01, 2013: Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infections with Pulmaquin and Lipoquin
Jun 17, 2013: Researchers Identify New Compound Effective Against Persistent And Drug-Resistant Tuberculosis
Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140
Dec 01, 2011: Vaccine Targeting Latent Tuberculosis Enters Clinical Testing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Mycobacterium Tuberculosis Infections, H2 2013
Products under Development for Mycobacterium Tuberculosis Infections - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
AstraZeneca PLC, H2 2013
GlaxoSmithKline plc, H2 2013
Affinium Pharmaceuticals, Inc., H2 2013
Oragenics, Inc., H2 2013
Ascenion GmbH, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Combination Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Mycobacterium Tuberculosis Infections Therapeutics - Drug Profile Updates
Mycobacterium Tuberculosis Infections Therapeutics - Dormant Products

List of Figures
Number of Products under Development for Mycobacterium Tuberculosis Infections, H2 2013
Products under Development for Mycobacterium Tuberculosis Infections - Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Discovery and Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Combination Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013 25

AstraZeneca PLC
GlaxoSmithKline plc
Affinium Pharmaceuticals, Inc.
Oragenics, Inc.
Ascenion GmbH

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos